In this Q&A, Minsu Kang, vice president ... experience engaging with the FDA in the context of rare disease therapies. Kang has over 10 years in CNS development, and extensive experience working on late-stage clinical trials and regulatory affairs for a number of neurodegenerative ... In this Q&A, Minsu Kang, vice president of clinical development and regulatory affairs at Polaryx Therapeutics, shares his insights from his firsthand experience engaging with the FDA in the context of rare disease therapies. Kang has over 10 years in CNS development, and extensive experience working on late-stage clinical trials and regulatory affairs for a number of neurodegenerative diseases. Polaryx, a publicly-traded, clinical-stage biotech is developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (LSD). Recent funding will allow the initiation of its Phase II SOTERIA trial, evaluating its lead compound across multiple LSD indications. Minsu Kang of Polaryx Therapeutics explains how to align with regulators on study design and maintain scientific rigor Many factors go into achieving alignment with the FDA on this topic, such as off-label uses of existing medications, disease severity, and availability of natural history data that may serve as an external control arm. Having a good scientific foundation and supporting data, beyond simply referring to the unmet medical needs, can be helpful in achieving regulatory alignment. BX: In your experience, has this alignment caused any friction with the clinical development plans or maybe trial amendments?

Original title: “Navigating FDA talks in rare disease programs”

In this Q&A, Minsu Kang, vice president ... experience engaging with the FDA in the context of rare disease therapies. Kang has over 10 years in CNS development, and extensive experience working on late-stage clinical trials and regulatory affairs for a number of neurodegenerative ... In this Q&A, Minsu Kang, vice president of clinical development and regulatory affairs at Polaryx Therapeutics, shares his insights from his firsthand experience engaging with the FDA in the context of rare disease therapies. Kang has over 10 years in CNS development, and extensive experience working on late-stage clinical trials and regulatory affairs for a number of neurodegenerative diseases. Polaryx, a publicly-traded, clinical-stage biotech is developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (LSD). Recent funding will allow the initiation of its Phase II SOTERIA trial, evaluating its lead compound across multiple LSD indications. Minsu Kang of Polaryx Therapeutics explains how to align with regulators on study design and maintain scientific rigor Many factors go into achieving alignment with the FDA on this topic, such as off-label uses of existing medications, disease severity, and availability of natural history data that may serve as an external control arm. Having a good scientific foundation and supporting data, beyond simply referring to the unmet medical needs, can be helpful in achieving regulatory alignment. BX: In your experience, has this alignment caused any friction with the clinical development plans or maybe trial amendments?

Original title: “Navigating FDA talks in rare disease programs”

Real-world data are becoming increasingly important in rare disease development, particularly where small trials cannot capture every aspect of patient experience. Yang said real-world evidence can help show how a therapy affects patients beyond a narrow clinical endpoint. “What it comes down to is the holistic approach,” he said. “Real-world data shows how a treatment ... Real-world data are becoming increasingly important in rare disease development, particularly where small trials cannot capture every aspect of patient experience. Yang said real-world evidence can help show how a therapy affects patients beyond a narrow clinical endpoint. “What it comes down to is the holistic approach,” he said. “Real-world data shows how a treatment is actually helping kids, and not just its effect on a small biomarker or certain symptoms. For companies developing therapies in pediatric lysosomal storage disorders, flexibility will be essential with newer models and approaches in rare disease trials. In conditions where patient numbers are small, disease progression is variable and treatment options remain limited, the success of a clinical program may depend as much on trial design as on the therapeutic mechanism itself. Safety, ease of administration, clinical benefit, quality of life and biomarker changes all contribute to the overall evidence package. For PLX-200, Yang pointed to the potential advantage of an oral solution that could be administered more easily than more invasive approaches used in some rare neurologic diseases. He contrasted the quality-of-life implications of a treatment taken at home with therapies that may require frequent hospital visits or invasive delivery procedures. This helps shape how the therapy’s overall value may be assessed. For pediatric rare diseases, a treatment that is safer, easier to administer and broadly applicable could have meaningful clinical and practical advantages.

Original title: “Why Rare Disease Trial Design Requires the “Right Patients at the Right Time” - Xtalks”

l nbdnj allosteric chaperone for multiple defective enzymes involved in lysosomal storage disorders lsds

Original title: “l-NBDNJ allosteric chaperone for multiple defective enzymes involved in lysosomal storage disorders (LSDs).”

caregiver reports of neurodevelopmental functions in pediatric lysosomal storage disorders a scoping review

Original title: “Caregiver Reports of Neurodevelopmental Functions in Pediatric Lysosomal Storage Disorders: A Scoping Review.”

PARAMUS, NJ - Polaryx Therapeutics , a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders , joins the global rare... The National Organization for Rare Diseases (NORD), a rare disease patient advocacy organization, notes that a disease is considered rare when it affects fewer than 1 in 2,000 people globally, with approximately 70% of these diseases starting in childhood. There are more than 6,000 rare diseases identified, 72% of which are genetically inherited. 'On Rare Disease Day, Polaryx proudly stands alongside the rare disease community - patients, families, caregivers, researchers, and advocacy partners to underscore the urgent need for new and transformative treatments,' said Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders ('LSDs'), joins the global rare disease community in raising awareness and supporting patients, families, caregivers, and healthcare providers. Rare Disease Day, observed annually on the last day of February, serves as an international campaign to raise awareness about the challenges faced by individuals and families living with rare diseases. ... SOTERIA is a Phase 2, open-label, single arm trial intended to assess the safety, tolerability, and clinical activity of Polaryx's lead drug candidate, PLX-200, in CLN2, CLN3, Krabbe disease, and Sandhoff disease, four different LSDs whose patient populations Polaryx believes represent approximately one quarter of the LSD population.

Original title: “Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders | MarketScreener India”

PARAMUS, NJ, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel,... The National Organization for Rare Diseases (NORD), a rare disease patient advocacy organization, notes that a disease is considered rare when it affects fewer than 1 in 2,000 people globally, with approximately 70% of these diseases starting in childhood. There are more than 6,000 rare diseases identified, 72% of which are genetically inherited. “On Rare Disease Day, Polaryx proudly stands alongside the rare disease community - patients, families, caregivers, researchers, and advocacy partners to underscore the urgent need for new and transformative treatments,” said Alex Yang, Chairman and Chief Executive Officer of Polaryx Therapeutics, Inc. For more information about Rare Disease Day, please visit www.rarediseaseday.org. ... SOTERIA is a Phase 2, open-label, single arm trial intended to assess the safety, tolerability, and clinical activity of Polaryx’s lead drug candidate, PLX-200, in CLN2, CLN3, Krabbe disease, and Sandhoff disease, four different LSDs whose patient populations Polaryx believes represent approximately one quarter of the LSD population. A natural history study is a preplanned observational study intended to track the course of the disease. Should the data demonstrate compelling clinical activity, Polaryx may seek conditional marketing authorization. ... Polaryx Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing patient-friendly small molecule and gene therapy treatments for rare orphan lysosomal storage disorders (LSDs).

Original title: “Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders”

These results are a significant step forward as Polaryx Therapeutics prepares for a Phase 2 trial to further evaluate PLX-200. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Polaryx selects CRO for phase 2 trial of rare disease treatment... Polaryx, a clinical-stage biotechnology company focused on developing treatments for rare pediatric lysosomal storage disorders, completed its initial public offering earlier this year. In other recent news, Polaryx Therapeutics has announced preclinical data regarding its drug candidate PLX-200, a reformulated version of gemfibrozil. (NASDAQ:PLYX) announced Tuesday it has selected a contract research organization (CRO) to conduct SOTERIA, a phase 2 trial evaluating its lead candidate PLX-200 across four rare lysosomal storage disorders (LSDs). The announcement comes as PLYX shares have experienced significant volatility, currently trading at $2.41, down 46.44% over the past week. The open-label, single-arm trial will assess PLX-200’s safety, tolerability, and clinical activity in patients with CLN2, CLN3, Krabbe disease, and Sandhoff disease - conditions that Polaryx estimates represent approximately one quarter of the LSD population. "Our selection of a CRO partner marks an important milestone for us as we continue to advance the clinical development of SOTERIA and move closer to the clinic," said Lisa Bollinger, Chief Medical Officer of Polaryx, in a press release statement. The company received a safe-to-proceed letter from the FDA in October 2025 and plans to initiate the trial in the first half of 2026 at sites in the United States, Europe, and potentially Asia. PLX-200 is an orally available compound comprised of gemfibrozil, an FDA-approved lipid regulating agent. According to the company, gemfibrozil’s ability to cross the blood-brain barrier has been documented in preclinical trials, which could be significant for treating these neurological disorders.

Original title: “Polaryx selects CRO for phase 2 trial of rare disease treatment By Investing.com”

These results are a significant step forward as Polaryx Therapeutics prepares for a Phase 2 trial to further evaluate PLX-200. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Polaryx selects CRO for phase 2 trial of rare disease treatment... Polaryx, a clinical-stage biotechnology company focused on developing treatments for rare pediatric lysosomal storage disorders, completed its initial public offering earlier this year. In other recent news, Polaryx Therapeutics has announced preclinical data regarding its drug candidate PLX-200, a reformulated version of gemfibrozil. (NASDAQ:PLYX) announced Tuesday it has selected a contract research organization (CRO) to conduct SOTERIA, a phase 2 trial evaluating its lead candidate PLX-200 across four rare lysosomal storage disorders (LSDs). The announcement comes as PLYX shares have experienced significant volatility, currently trading at $2.41, down 46.44% over the past week. The open-label, single-arm trial will assess PLX-200’s safety, tolerability, and clinical activity in patients with CLN2, CLN3, Krabbe disease, and Sandhoff disease - conditions that Polaryx estimates represent approximately one quarter of the LSD population. "Our selection of a CRO partner marks an important milestone for us as we continue to advance the clinical development of SOTERIA and move closer to the clinic," said Lisa Bollinger, Chief Medical Officer of Polaryx, in a press release statement. The company received a safe-to-proceed letter from the FDA in October 2025 and plans to initiate the trial in the first half of 2026 at sites in the United States, Europe, and potentially Asia. PLX-200 is an orally available compound comprised of gemfibrozil, an FDA-approved lipid regulating agent. According to the company, gemfibrozil’s ability to cross the blood-brain barrier has been documented in preclinical trials, which could be significant for treating these neurological disorders.

Original title: “Polaryx selects CRO for phase 2 trial of rare disease treatment By Investing.com”